Reduction of fatigue in Sjögren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study

Annals of the Rheumatic Diseases

Volumn 67, Issue 11, 2008, Pages 1541-1544

  Dass, S ^a   Bowman, S J ^b   Vital, E M ^a   Ikeda, K ^a   Pease, C T ^a   Hamburger, J ^c   Richards, A ^c   Rauz, S ^d   Emery, P ^a,e  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b SELLY OAK HOSPITAL   (United Kingdom)

^c BIRMINGHAM DENTAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PLACEBO; RITUXIMAB;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INFUSION; FATIGUE; FEVER; GASTROENTERITIS; HEADACHE; HEART PALPITATION; HUMAN; MENINGISM; PAIN ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; SERUM SICKNESS; SHORT FORM 36; SJOEGREN SYNDROME; TREATMENT OUTCOME; URTICARIA; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATIGUE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 54349116244     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.083865     Document Type: Article

References (17)

1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002;61:554-8.
2. Bjerrum K, Prause JU. Primary Sjögren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 1990;8:283-8.
3. Bowman SJ, Pillemer S, Jonsson R, Asmussen K, Vitali C, Manthorpe R, et al. Revisiting Sjögren's syndrome in the new millennium:perspectives on assessment and outcome measures. Rheumatol 2001;40:1180-8.
4. Bowman SJ, Booth DA, Platts RG, UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Rheumatol 2004;43:758-64.
5. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Scand J Rheumatol 2000;29:341-8.
6. van der Reijden WA, Vissink A, Veerman EC, Amerongen AV. Treatment of oral dryness complaints in Sjögren's syndrome. Ann Rheum Dis 1999;58:465-74.
7. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren's syndrome. Arthritis Rheum 2004;50:1270-76.
8. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren's syndrome. Arthritis Rheum 2004;50:2240-45.
9. Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren's syndrome. Ann Rheum Dis 2005;64:1050-5.
10. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective clinical study by the European Concerted Action on Sjögren's syndrome. Arthritis Rheum 1999;42:1765-72.
11. Pijpe J, van Imhoff GW, Spijkervet FKL, Roodenburg JLN, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
12. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers J-O, Daridon C, Jousse-Jolin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:310- 17.
13. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
14. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
15. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-38.
16. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
17. Lwin CT, Bishay M, Platts RG, Booth DA, Bowman SJ. The assessment of fatigue in primary Sjögren's syndrome. Scand J Rheum 2003;32:33-7.